Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Reorganizes, Reports Preliminary Q4 Revenues Up 20 Percent

NEW YORK (GenomeWeb) – Luminex announced before the opening of the market on Monday that it expects to report fourth quarter revenues of $72 million, and 2016 revenue of $271 million, beating the average analyst estimates of $70.3 million and $268.9 million, respectively.

The preliminary revenues were up 20 percent in Q4 and 14 percent in 2016 over the prior-year periods.

Luminex also said that Verigene-related revenues rose to $9 million in Q4, up 32 percent from the prior year. The firm took ownership of the Verigene multiplexed molecular diagnostics platform when it acquired Nanosphere in 2016 for $77 million.

Luminex said that last month it reorganized “to both facilitate the integration of Nanosphere and to better focus” on its core business, reducing its headcount by more than 50 employees, reallocating responsibilities within the R&D organization, and “significantly” reducing its biodefense efforts. 

The firm added that due to the reorganization it will recognize a charge of around $2.5 million in Q4, and that it expects to save around $9 million.

Luminex also said it expects fiscal year 2017 revenue of $295 million to $305 million. The average Wall Street estimate is for revenues of $293.7 million.

Luminex shares were up nearly 4 percent to $21.15 in mid-morning trading on the Nasdaq. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.